K858 (Racemic)
K858 Racemic is an ATP-uncompetitive inhibitor of kinesin Eg5 with an IC50 of 1.3 μM.
Product Specifications
CAS Number
72926-24-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Kinesin
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/K858.html
Purity
99.93
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(NC1=NN(C(C)=O)C(C2=CC=CC=C2)(C)S1)=O
Molecular Formula
C13H15N3O2S
Molecular Weight
277.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Nakai R, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 2009 May 1;69 (9) :3901-9.|[2]De Iuliis F, et al. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. Invest New Drugs. 2016 Aug;34 (4) :399-406.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Kinesin-5/Eg5/KSP
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740633-100 1x 100 µL
Von Willebrand Factor (3E2D10), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741231-500 1x 500 µL
Eosinophil Peroxidase (AHE-1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400669-500 1x 500 µL
P27 / KIP1 (SX53G8), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
